Ocular Imaging Research and Reading Center

What We Do

The OIRRC is a comprehensive research center that specializes in providing ocular image acquisition and interpretation services for multicenter clinical trials.

Who We Are

The OIRRC brings together a diverse group of clinician scientists from across the globe with common goals: to promote a better understanding of various ocular diseases and to improve and enhance current treatment options.

Our Purpose

The OIRRC not only serves as the central place for evaluating the images from clinical trials but also leads several studies to identify biomarkers that may allow early identification of diseases and their responses to therapy using non-invasive, cutting edge imaging techniques.

Capabilities

OIRRC has the capacity to grade and interpret imaging data acquired with a multitude of devices and various technologies including but not limited to;

Optical Coherence Tomography

  • Heidelberg Spectralis
  • Zeiss Cirrus
  • Topcon
  • Optovue
  • Nidek

Fundus Autofluorescene

  • Heidelberg Spectralis
  • Optos
  • Zeiss

Fluorescein Angiography

  • Optos
  • Zeiss
  • Heidelberg Spectralis
  • Topcon
  • Kowa

Colored Fundus Photos

  • Nidek
  • Optos
  • MAIA

Microperimetry

  • Nidek
  • Optos
  • MAIA

Electrophysiology

  • Diopsys
  • Veris
  • Diagnosys

Adaptive Optics

  • RTX-1 Imagine Eyes

Wide Angle Imaging

  • Optos
  • Heidelberg Spectralis

Experience

OIRRC has provided reading center services to multiple Clinical Trials including but not limited to:

• ACTH as A Re-emerging theRapy for Uveitis (ACTHAR) NCT02931175

• A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (DME) – VIDI Study NCT02302079

• A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema – The iDEAL Study NCT01565148

• Sirolimus as Therapeutic Approach to Uveitis – SAVE Study NCT00908466

• Intravitreal Sirolimus as Therapeutic Approach to Uveitis – SAVE-2 NCT01280669

• The READ-2 Study: Ranibizumab for Edema of the mAcula in Diabetes NCT00407381

• Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose – the READ 3 Study NCT01077401

• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis NCT01960348

• Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration NCT02530918

• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI) NCT02247531

• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA) NCT02247479

• Study to Evaluate Effects of Emixustat Hydrochloride in Subjects with Proliferative Diabetic Retinopathy NCT02753400

• Study of the Safety, Tolerability, and Bioactivity of Tocilizumab on Patients with Non-infectious UVEITIS: The STOP-UVEITIS Study NCT01717170

policies & procedures

OIRRC ensures quality service with study updates, secured data storage, and 24/7 customer support.

Contact Us

333 W Maude Ave. #108 Sunnyvale, CA 94085
(323) 54-OIRRC (64772)